Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. has a significant institutional shareholder position reported by Bank of America Corporation and certain of its wholly owned subsidiaries. Bank of America reports beneficial ownership of 857,318 shares of common stock, representing 5.9% of the class, based on 14,607,286 shares outstanding as referenced from an issuer Form 8-K exhibit.

The position is held with no sole voting or dispositive power, but with shared voting power over 857,306 shares and shared dispositive power over 857,318 shares. The filing attributes the holdings to multiple affiliated entities, including BofA Securities, Inc., Bank of America, N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware, with Bank of America Corporation filing on their behalf.

Key Figures

Shares beneficially owned: 857,318 shares Percent of class: 5.9% Shared voting power: 857,306 shares +3 more

6 metrics

Shares beneficially owned 857,318 shares Bank of America Corporation beneficial ownership of Inhibrx Biosciences common stock

Percent of class 5.9% Ownership percentage of Inhibrx Biosciences common stock reported by Bank of America

Shared voting power 857,306 shares Shares over which Bank of America has shared power to vote or direct the vote

Shared dispositive power 857,318 shares Shares over which Bank of America has shared power to dispose or direct disposition

Shares outstanding basis 14,607,286 shares Outstanding Inhibrx Biosciences shares used to calculate 5.9% ownership, as of April 7, 2026

CUSIP 45720N103 CUSIP number for Inhibrx Biosciences, Inc. common stock

Key Terms

beneficial ownership, shared voting power, shared dispositive power, parent holding company or control person, +1 more

5 terms

beneficial ownership financial

"The beneficial ownership calculation relies on the 14,607,286 outstanding shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared voting power financial

"Shared Voting Power 857,306.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 857,318.00"

parent holding company or control person regulatory

"being reported on by the Parent Holding Company or Control Person"

broker dealer registered under section 15 of the Act regulatory

"a broker dealer registered under section 15 of the Act"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 12:27 PM Accepted by SEC EDGAR 08/03/2026 - 12:26 PM Learn about SEC filing dates

FAQ

What ownership stake in INBX does Bank of America report on this Schedule 13G?

Bank of America reports beneficial ownership of 857,318 shares of Inhibrx Biosciences (INBX) common stock, representing 5.9% of the outstanding class based on 14,607,286 shares referenced from an issuer Form 8-K exhibit.

How much voting power over INBX shares does Bank of America have?

Bank of America reports no sole voting power but shared voting power over 857,306 shares of Inhibrx Biosciences (INBX) common stock. It also reports shared dispositive power over 857,318 shares and no sole dispositive power.

What share count was used to calculate Bank of America’s 5.9% INBX ownership?

The 5.9% ownership is calculated using 14,607,286 outstanding shares of Inhibrx Biosciences (INBX), as disclosed in the issuer’s Form 8-K Exhibit 99.1, which reports share totals as of April 7, 2026.

Which Bank of America entities are associated with the INBX holdings?

The holdings are attributed to Bank of America Corporation and wholly owned subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware.

Does Bank of America hold INBX shares directly or through shared authority?

Bank of America reports 0 shares with sole voting or dispositive power and instead reports shared voting power over 857,306 shares and shared dispositive power over 857,318 shares of Inhibrx Biosciences (INBX) common stock.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Inhibrx Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45720N103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45720N103

1

Names of Reporting Persons

BANK OF AMERICA CORP /DE/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 857,306.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 857,318.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

857,318.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.9 %

12

Type of Reporting Person (See Instructions)

HC

Comment for Type of Reporting Person: The beneficial ownership calculation relies on the 14,607,286 outstanding shares disclosed in the Form 8-K - EXHIBIT 99.1 by the issuer on June 3, 2026, which reports share totals as of April 7, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Inhibrx Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CALIFORNIA, 92037.
Item 2.
(a)	Name of person filing: BANK OF AMERICA CORP /DE/
(b)	Address or principal business office or, if none, residence: 100 N TRYON ST CHARLOTTE, NC 28255
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 45720N103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 857,318.00
(b)	Percent of class: 5.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 857,306.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 857,318.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); Merrill Lynch International, a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); Merrill Lynch Pierce Fenner & Smith, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); and U.S. Trust Co of Delaware, a corporation which holding does not exceed one percent of the reported securities.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BANK OF AMERICA CORP /DE/

Signature:	/s/ Monica Yako
Name/Title:	Authorized Signatory
Date:	08/03/2026